In patients with compensated hepatitis B cirrhosis, the indications for treatment are HBV DNA ≥104 copies/mL for HBeAg-positive patients and HBV DNA ≥103 copies/mL for HBeAg-negative patients, regardless of normal or elevated ALT. The goal of treatment is to delay or reduce the occurrence of liver failure and HCC. Because of the need for longer-term treatment, nucleoside (acid) analogs with a low incidence of drug resistance are preferable, and their discontinuation criteria are unclear. In patients with decompensated hepatitis B cirrhosis, as long as HBV DNA can be detected, regardless of whether ALT or AST is elevated, timely antiviral therapy with nucleoside (acid) analogs is recommended based on informed consent to improve liver function and delay or reduce the need for liver transplantation. Because of the need for long-term treatment, nucleoside (acid) analogs with a low incidence of drug resistance should be used, and should not be discontinued at will. In the event of drug resistance mutations, other approved nucleoside (acid) analogs that can treat drug resistance mutations should be added promptly.